Wendy White

RareiTi Inc.                                                                                                      2020-Present
RareiTi is a new model for compassionate use and managed care. The global, tech enabled platform provides patients and caregivers with care beyond therapy and pharmaceutical companies with real world evidence and invaluable patient insights.

TREND Community
Advisor                                                                                                            2018-Present
TREND Community’s mission is to improve the quality of life for all of us living with rare and chronic disease by leveraging social media to better understand disease burden “turning antidotes into evidence.” The AI supporting the proprietary algorithm is based on 1.5 million data points and has been used as supporting evidence in FDA submissions. As a member of the advisory board, helping hone their value proposition and develop their business model.

Wendy White Consulting                                                                                 2017-2019
Uses experience, expertise and network to audit/augment commercial plans to delivery of rare disease services. This includes identifying opportunities for technological and operational efficiencies of patient services for a large corporation serving small communities, developing patient centered strategies for a European company to launch a rare disease therapy with no existing patient groups and identifying gaps and opportunities for improvement in patient services for U.S. biotech companies.

 Vitrisa Therapeutics, Inc.                                                                                 2018-2019
Chief Patient Officer
Represented the patient voice in all executive decisions and communications internally and externally. Helped research, define and communicate the unmet need in investment pitches. Gathered support and partnered with relevant patient communities. Worked with the Chief Science Officer to rank disease targets using proprietary technology based on the patient landscape and unmet need.

Dohmen Life Science Services                                                                        2015-2016
Senior Vice-President, Rare Disease
General Manager, Siren Interactive Corporation
Siren Interactive Corporation was acquired in January 2015 by Dohmen Company as part of a rollup of rare disease service organizations. Charged with integrating research-based behavioral services into the existing exclusive specialty pharmacy model to better address the unmet needs of patients on ultra-orphan (expensive) therapies. Results included immediate return on engagement with clinical team and patient satisfaction scores leading to higher adherence rates and better patient outcomes.

Siren Interactive Corporation                                                                          1999-2014
Founder & CEO
The first digital-based, relationship marketing agency focused exclusively on understanding the behaviors of patients and physicians dealing with chronic rare diseases. Drove new patient starts and lifelong adherence to therapies for clients. Helped increase valuations through development of strategy and oversight of implementation to build databases of rare patients as an analog for sizing the market at launch.

  •   5000 List of fastest growing privately held companies for 2010, 2011, 2012 and 2013
  • The nation’s first agency to certify its staff in regulatory compliance for both Patient Relationship Marketing (PRM) and Internet Promotion/Social Media.